

## Potential of copper alloys to kill bacteria and reduce hospital infection rates

Harold T. Michels<sup>1</sup>, Corinne A. Michels<sup>2</sup>

### Author Details:

<sup>1</sup>Copper Development Association, 260 Madison Avenue, New York, NY 10016

<sup>2</sup>Biology Department, Queens College, City University of New York, 65-30 Kissena Boulevard, Queens, NY 11367

### Correspondence:

Harold T, Michels, PhD, Copper Development Assoc., 260 Madison Ave., New York, NY 10016; 212-251-7224

**E-mail:** harold.michels@copperalliance.us

### Abstract

A large body of peer-reviewed literature has demonstrated in laboratory testing that placing bacteria in a highly concentrated bacterial inoculum onto copper alloy surfaces results in their rapid death. A smaller but convincing number of studies indicate that bacteria die on the surfaces of hospital room components made from copper alloys. Will the ability of copper alloys to kill bacteria translate into an ability to reduce the rate of hospital-acquired infections (HAIs)? This review addresses this question. In particular, the results of a clinical trial in which HAI rates are significantly reduced after introducing copper alloys components into Intensive Care Units of three hospitals will be presented. The findings suggest that copper alloys enhance hospital hygiene protocols because they act passively 24/7/365 requiring neither training nor human intervention to kill bacteria and reduce hospital-acquired infections.

**Key words:** Antimicrobial copper alloys, hospital-infections (HAIs), clinical trial, bacterial burden, infection rates, VRE, MRSA, contact killing.

## Introduction

Hospital-acquired infections (HAIs), or those infections the patient develops while in the hospital, continue to be a concern because they are not only costly to treat, but more importantly, cause human suffering and even death. It was reported that, in 2002, 1.7 million patients develop an infection while being cared for in U.S. hospitals and about 99,000 die each year (1). Annual treatment costs alone for these infections are estimated to be in the range of \$35 billion (2). This translates into approximately 4,600 infections resulting in about 274 deaths each day. In spite of extensive efforts to increase hand-washing compliance-an obvious, very simple, and important method to help reduce transmission of bacteria-has not been sufficient on its own to solve the infection problem.

Surface disinfectants are another widely employed and useful method to help reduce the amount of bacterial on environmental surfaces. Evidence that contaminated surfaces can function as transmission vectors for hospital pathogens is clear and control of surface contaminants should be an effective approach to controlling HAIs (3). Hygiene standards for surface cleanliness, based upon food processing industry standards, have been proposed (4). However, even when improved hand washing compliance and diligent surface hygiene disinfection are combined, hospital infections are still a serious health issue. Newer technologies, such as UV light units (5, 6) and various hydrogen peroxide (HP) systems (6), can effectively decontaminate hospital rooms, but, when added the hand washing and surface disinfection, HAIs are still not completely controlled. All the above approaches-hand washing, surface disinfection, UV light and HP systems-have one thing in common, they are episodic or one-time approaches. Therefore, as soon as the decontamination process ends, microbial contaminants can again begin to accumulate. Adding an additional technology that is

continuously active-antimicrobial copper alloys-can alleviate this problem. Placing surfaces made from 100% antimicrobial copper alloys will provide a continuously active solid surface that kills bacteria on contact and thus has the potential to reduce infections. Here we review the clinical evidence supporting this potential.

## Laboratory Research

A multitude of laboratory studies have shown that a wide variety of bacteria, both Gram-positive and Gram-negative, are killed after being placed on copper alloys surfaces, including "hospital superbugs" such as Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Vancomycin-Resistant *Enterococcus* (VRE). Many of these studies have been summarized in previously published reviews (7, 8). Also described elsewhere is the metallurgy of various antimicrobial copper alloys and their postulated killing mechanisms (8). These studies indicate that copper alloy surfaces act as an effective biocide not only on a broad range of bacteria but also are active against fungi and permanently inactivate viruses. Table 1 lists the microorganisms that have shown sensitivity to copper alloy surface contact killing.

Clearly, copper alloy surfaces have the potential to be useful in controlling a wide variety of microbes in the hospital setting but this needs to be confirmed in clinical trials. Laboratory tests are conducted under ideal controlled conditions. The surfaces of the test samples are sanitized prior to being inoculated with a known concentration of a known strain of bacteria. In contrast, clinical samples are collected in hospitals by taking swabs from the surfaces of components. One does not know when the surface became contaminated and the hospital surface is typical contaminated with several different species of bacteria. The surfaces analyzed in a clinical test may also contain residues from

prior cleaning solutions, oil from the hands after being touched, and other chemical contaminants. Also noteworthy is that, in laboratory test conditions, the bacterial inoculum concentration is typically very high, on the order of 10 million colony-forming units per sq. cm. ( $10^7$  CFU/cm<sup>2</sup>). When the surface of a hospital component is sampled, swabs are usually taken from 100 cm<sup>2</sup> area and bacterial contamination ranges from 1,000 to 10,000 CFU/ 100 cm<sup>2</sup>, depending on when the surface was cleaned or the frequency at which the surface is touched.

As explained above, laboratory tests are conducted by inoculating samples with an exceedingly high numbers of bacteria, well above the amount that would ordinarily be found on surfaces in hospitals. The demonstrated ability of copper alloys to kill these high numbers of bacteria in laboratory tests is a strong testament to their efficacy and bodes well for hospital-based studies. Nonetheless, antimicrobial copper alloys need to undergo testing in the real life clinical environment.

### **Clinical Results – microbial reduction**

Microbial burden is not only a surrogate measure of cleanliness. It is also is an indicator of the propensity to acquire an infection, as will be discussed in a later section. A clinical study conducted in a medical intensive care unit (MICU) in the United States (9) measured the amount of bacteria present on 36 standard plastic patient bed rails immediately before cleaning and at set time intervals of 0.5, 2.5, 4.5, and 6.5 hours after cleaning with either of two hospital-approved disinfectants. The bacterial burden rebounded 30% at 6.5 hours after using one type of disinfectant and 45% at 2.5 hours after using another disinfectant. Thus, cleaning helps reduce bacterial burden, but its benefit is dissipated in a matter of hours.

In a subsequent study in the same hospital setting (10), three beds were custom fitted with copper alloy surface caps to cover the bed rails, with three standard plastic beds serving as control surfaces. The sampling schedule was the same as described in the previous study (9), but in contrast to the previous study, only one hospital-approved disinfectant was used. The bacterial burdens found on the copper rails were significantly lower than those measured on the standard plastic bed rails, as shown in Figure 1. Note that the copper rail bacterial burden approaches the suggested “terminal cleaning” target of 250 CFU/100 cm<sup>2</sup>, which is the cleaning goal after a room is vacated but prior to introducing the next patient.

In the United States (11), another small trial was conducted in an outpatient infectious disease clinic. In this environment, surfaces are touched by many patients and rapidly become contaminated. Copper alloys were installed on two phlebotomy chairs. The tops of the wooden arms of the chairs were inlaid with a wide copper alloy strip, but the wood remained on the sides of the arms. In addition, the plastic trays attached to the chair arms were replaced with copper alloy trays. Over 15 weeks, 437 patients used the chairs. Results were compared to the control surfaces, the wooden arms and plastic trays on the chairs in adjacent rooms. Cleaning frequency and methods were the same. The copper tray chairs showed an 88% reduction in bacterial burden and the copper alloy inlaid arm showed a 90% reduction compared to the standard surfaces or controls. Even the remaining wood at the side of the copper alloy inlaid chair arm displayed a 70% reduction, which was attributed to lower rate of cross contamination from the copper alloy surface. Fewer bacteria survived on the copper alloy surface and therefore a smaller number of bacteria were available to be transferred to the adjacent wood on the side of the arm of the chair.

In a clinical trial conducted in a hospital medical ward in England (12), three copper alloy components were installed: sink faucet handles, door push plates at the ward entrance, and toilet seats. Each of these surfaces was sampled once each week at 7 am and 5 pm over a ten-week period, as were equivalent non-copper control items in the ward. After five weeks the components were interchanged. The median bacterial burden reduction on the copper components compared to the control components ranged from 90% to 100%.

In a second larger clinical trial conducted in the medical ward of the same hospital in England mentioned above (13), several frequently touched components made from copper alloys were installed including door handles and push plates, grab rails, light switches and pull cord toggle switches, over-the-patient bed tables, dressing trolleys, as well as portable commodes, sink taps and fittings, sinks, toilet seats and flush handles. The above copper components and the controls were sampled once a week for 24 weeks, with the locations of the components being switched after 12 weeks. The microbial burden on 8 of the 14 copper alloy components was significantly lower than those found on the standard control components. While the other 6 copper alloy components also exhibited a reduction in bacterial burden, it was found not to be statistically significant. However, indicator organisms recovered from all surfaces provide some additional insights. The surfaces of copper alloy components harbored significantly fewer VRE, MRSA and coliform bacteria, compared to the control surfaces.

A clinical trial was conducted in a hospital in Germany (14), in patient rooms, rest rooms, and staff rooms, and in oncology, respiratory treatment, and geriatric wards of a hospital. A total of 48 aluminum door push plates were replaced with copper alloy plates. An equal number aluminum doorknobs and

plastic light switches were also replaced with components made from copper alloys. During 16 weeks in the summer and 16 weeks in the winter, samples were taken from the copper alloy surfaces and control surfaces. The total bacterial burden on the copper alloy components was 63% of that found on the control components. The total bacterial burden on copper alloy doorknobs was much lower than that found aluminum doorknobs. The bacterial burden on the both the copper push plates and light switches was only slightly lower than that found on the controls made of aluminum or plastic. In addition the bacterial burden seen on the aluminum doorknobs, while higher than that found on the copper doorknobs, was also much higher than seen on the other control components. It was suggested that this difference may be simply because that doorknobs are more frequently touched relative to the other components. While the results of this trial did not achieve the same high levels of microbial burden reduction observed in other trials, the impact of the presence of antimicrobial copper alloys is apparent.

A clinical trial conducted in a Pediatric ICU in Chile involved 8 room with copper components and 8 control rooms with standard components (15). The copper surfaces included in the study were bed rails, bed rail levers, IV poles, faucet handles, and a workstation surface. The results indicated that copper alloys efficacy was equivalent to that observed in an adult ICU (16). The copper bed rail, the most frequently touched object in the rooms, showed the greatest bacterial burden. Interestingly, it was reported that the introduction of copper alloys in the study rooms suppressed the microbial burden recovered from components in the nearby control rooms, collected prior to the introduction of the copper components. It is suggested that this may be a result of suppressed cross contamination.

Another clinical trial in the United States was conducted in the medical-surgical suite in a small rural hospital (17). Six of the 13 single rooms were converted to copper, as were three of the five double rooms. The installed copper alloy components included door levers, alcohol gel dispenser push plates, light switches, bedside table pulls, over-bed tables, toilet flush valve lever, grab bars, faucet handles, and soap dispenser push plates. Copper alloy beds were not fabricated, but a commercial copper alloy stretcher bed, used for patient transport by the emergency department, was included in the trial. The mean bacterial burden recovered from the copper alloy components was 140 CFU/100 cm<sup>2</sup>, which is well below the 8,414 CFU/100 cm<sup>2</sup> found on the controls and slightly below the terminal cleaning target level of 250 CFU/100 cm<sup>2</sup>.

A large clinical trial was conducted in the United States in the ICUs of three hospitals over 43 month period (16). At month 23, six copper components were installed in eight of the sixteen ICU rooms. The components were the rail of the patient bed, the nurses call button, the arms of the visitor's chair, the over-the-patient bed table, the intravenous (IV) drip pole, and a data input device that varied by hospital. The latter was either a computer mouse, the bezel on a touch screen, or a strip where the palm of the hand rests on a laptop computer. Microbial burden was measured on the six copper components and six standards components that served as controls over the next 21 months. The data collected from the six objects is presented in Figure 2. Note that the control bed rail has the highest level of microbial burden, but this is dramatically lower on the copper bed rail. The bed rail is the major point of interaction between patients, healthcare workers and visitors, which may explain the high microbial burden on the plastic bed rail. The controls for the nurses call button and arms of the visitor's

chair also had high levels of contamination. However, the bacterial burden on all the copper components were below that seen on the standard or control surfaces, except for the data input devices, which is an anomaly. The contamination levels of both the control and copper data input devices were both low. The use of these devices is restricted to healthcare professionals who are more aware of the potential for infections and may clean them and their hands more frequently.

### **Clinical Results –infection reduction**

A follow-on study (18), conducted at the same facility in Chile as described previously (15), analyzed hospital-acquired infections in 261 patients in the copper rooms and 254 in the control rooms. The study found that infection rates were 10.6 per 1000 patient days in the copper room and 13.0 in the control rooms. This translated into a relative risk reduction of 0.19. These authors reported that the above result was not did not achieve statistical significance and concluded, "Conducting clinical trials to assess interventions that may impact HAI rates is very challenging."

A next phase of the previously mentioned clinical trial in the United States (16), also conducted in the ICUs of three hospitals, shifted its focus from microbial burden to infection rates (19). The sampling continued as previously described but the healthcare workers were not informed that that approval had been granted by the Internal Review Boards of all the involved institutions to track infections. The number of infections over the same time period in copper and control rooms were compared. Clinicians at each hospital determined incidents of hospital-acquired infections, according to National Safety Network definitions. However, the clinicians were "masked" or "blinded" with regard to the identity of patients. The infection rates were 3.4% in the copper rooms (10 infections in 294 patients)

and 8.1% in the control rooms, or 26 fewer infections than in the 320 control patients. A high level of statistical significance ( $p$  value =0.013) was attained. This equates to 58% reduction in infections as a result of introducing only six copper items into each copper room, comprising less than 10% of their surface area. The data plotted in Figure 3, collected during this clinical trial, indicates that the propensity to acquire an infection increases as the microbial burden increases. Thus, infection rates correlate with surface contamination levels. The figure includes all data from both copper and control rooms, and is statistically significant, as indicated by its  $p$  value of 0.038. The results of this (18) can be used to calculate the cost of recovery time for outfitting a copper alloy room. The additional cost to fabricate the copper components was about \$52,000. The cost to treat an infection ranges from \$28,400 to \$33,800 (2). The number of infections prevented in this trial is 14. Based upon the above cost per infection, the time to recover the cost of outfitting the ICU with copper components is calculated as 37 to 44 days (7).

### Conclusions

There is a considerable body of literature that indicates that bacteria die when they come into contact with copper alloy surfaces in the laboratory as well as a meaningful but smaller number of publications that illustrate that copper alloys kill bacteria in the clinical setting. While additional clinical trials are needed to confirm that the deployment of solid copper alloy surfaces can reduce infection rates, there is ample evidence currently available to encourage hospitals and other patient treatment centers to adopt the use of antimicrobial copper alloys as part of their infection control protocols.

The copper alloy components used in the studies referenced here were fabricated from 100% solid metal. The copper alloys

used must contain at least 60% copper to be considered for EPA registration, which is required in make public health claims in the United States related to their ability to kill specific bacteria. The copper alloy was not applied as a coating, which can wear off, or introduced as particles in proprietary plastic matrix that make up less than 5% of the surface area.

The initial cost of outfitting a copper alloy room may be perceived as an issue. However, the extra cost can be quickly recovered because infections are expensive to treat. Based upon the number of infections prevented in ICUs of three hospitals (19), the extra cost of copper components was recaptured in less than two months (7). It should also be noted that some hospitals would lose a portion of their Medicare funding under the Hospital Acquired Condition Reduction Program (20) if hospital-acquired infections occur in their facilities. It is important to note that there is no identified medical risk in using antimicrobial copper alloy hospital room components. Humans have commonly used copper alloys since the Bronze Age, over 5 millennia ago, without any evidence of harm. Clearly, placing copper alloy components in the human environment has the potential to reduce infections, may avoid the above-mentioned financial penalty, and will lower infection treatment costs. Antimicrobial copper alloys may also have intangible benefits, such as, demonstrating to your patients that your organization cares about their wellbeing.

Perhaps the greatest potential benefit of wider use of antimicrobial copper alloys to control infection has the potential to inhibit the emergence of new antibiotic resistant strains. Based on reports from the U.S. Center for Disease Control, the abuse and overuse of antibiotics is a major cause of the emergence of resistant bacteria (<http://www.cdc.gov/drugresistance/>). The use of sub-clinical levels of antibiotics in raising animals

for human consumption is a serious contributor to this problem (21). Also to be considered is that horizontal gene transfer of antibiotic resistance, a major cause of the spread of multidrug resistance in bacteria, is essentially blocked by copper alloy surface killing because the bacteria die rapidly with few to no survivors (22).

Nearly 200 facilities have installed antimicrobial copper products provided by U.S. based EPA registered manufacturers, in 37 states and 13 countries. These installations include healthcare facilities, schools and universities, office buildings, fitness facilities, laboratories and restaurants. Copper alloys are a passive antimicrobial technology that works 24 hours/day, 7 days/week, and 365 days/year. Its effectiveness in killing bacteria and potentially reducing infections requires neither specially trained personnel nor human intervention. A wide array of commercial products made from EPA-

registered antimicrobial copper alloys is available for integration into the healthcare environment.

In summary, consideration should be given to deploy components made from solid metal antimicrobial copper alloys as an additional tool in the fight to reduce hospital-acquired infections.

### **Acknowledgements**

We thank Adam Estelle of the Copper Development Association for his useful input, as well as the many investigators with whom we have interacted over the years, especially Professors Michael G. Schmidt and C. William Keevil.

### **Conflict of Interest**

The authors have no conflict of interest directly relevant to this manuscript.

**References**

1. **Klebens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM.** 2007. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep Wash DC* 1974 **122**:160–166.
2. **Scott, R. Douglas.** 2009. The Direct Medical Cost of Healthcare-Associated Infections in U. S. Hospitals and the Benefits of Prevention. CS200891-A. Centers for Disease Control and Prevention.
3. **Otter JA, Yezli S, Salkeld JAG, French GL.** 2013. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. *Am J Infect Control* **41**:S6–11.
4. **Dancer SJ.** 2004. How do we assess hospital cleaning? A proposal for microbiological standards for surface hygiene in hospitals. *J Hosp Infect* **56**:10–15.
5. **Boyce JM, Havill NL, Moore BA.** 2011. Terminal decontamination of patient rooms using an automated mobile UV light unit. *Infect Control Hosp Epidemiol* **32**:737–742.
6. **Rutala WA, Weber DJ.** 2011. Are room decontamination units needed to prevent transmission of environmental pathogens? *Infect Control Hosp Epidemiol* **32**:743–747.
7. **Michels HT, Keevil CW, Salgado CD, Schmidt MG.** 2015. From Laboratory Research to a Clinical Trial: Copper Alloy Surfaces Kill Bacteria and Reduce Hospital-Acquired Infections. *HERD* **9**:64–79.
8. **Michels HT, Michels CA.** 2016. Copper alloys - The new “old” weapon in the fight against infectious disease. *Curr Trends Microbiol* **10**:23 – 46.
9. **Attaway HH, Fairey S, Steed LL, Salgado CD, Michels HT, Schmidt MG.** 2012. Intrinsic bacterial burden associated with intensive care unit hospital beds: effects of disinfection on population recovery and mitigation of potential infection risk. *Am J Infect Control* **40**:907–912.
10. **Schmidt MG, Attaway Iii HH, Fairey SE, Steed LL, Michels HT, Salgado CD.** 2013. Copper continuously limits the concentration of bacteria resident on bed rails within the intensive care unit. *Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am* **34**:530–533.
11. **Rai S, Hirsch BE, Attaway HH, Nadan R, Fairey S, Hardy J, Miller G, Armellino D, Moran WR, Sharpe P, Estelle A, Michel JH, Michels HT, Schmidt MG.** 2012. Evaluation of the antimicrobial properties of copper surfaces in an outpatient infectious disease practice. *Infect Control Hosp Epidemiol* **33**:200–201.
12. **Casey AL, Adams D, Karpanen TJ, Lambert PA, Cookson BD, Nightingale P, Miruszenko L, Shillam R, Christian P, Elliott TSJ.** 2010. Role of copper in reducing hospital environment contamination. *J Hosp Infect* **74**:72–77.
13. **Karpanen TJ, Casey AL, Lambert PA, Cookson BD, Nightingale P, Miruszenko L, Elliott TSJ.** 2012. The antimicrobial efficacy of copper alloy

- furnishing in the clinical environment: a crossover study. *Infect Control Hosp Epidemiol* **33**:3–9.
14. **Mikolay A, Huggett S, Tikana L, Grass G, Braun J, Nies DH.** 2010. Survival of bacteria on metallic copper surfaces in a hospital trial. *Appl Microbiol Biotechnol* **87**:1875–1879.
  15. **Schmidt MG, von Dessauer B, Benavente C, Benadof D, Cifuentes P, Elgueta A, Duran C, Navarrete MS.** 2016. Copper surfaces are associated with significantly lower concentrations of bacteria on selected surfaces within a pediatric intensive care unit. *Am J Infect Control* **44**:203–209.
  16. **Schmidt MG, Attaway HH, Sharpe PA, John J, Sepkowitz KA, Morgan A, Fairey SE, Singh S, Steed LL, Cantey JR, Freeman KD, Michels HT, Salgado CD.** 2012. Sustained reduction of microbial burden on common hospital surfaces through introduction of copper. *J Clin Microbiol* **50**:2217–2223.
  17. **Hinsa-Leasure SM, Nartey Q, Vaverka J, Schmidt MG.** 2016. Copper alloy surfaces sustain terminal cleaning levels in a rural hospital. *Am J Infect Control* **44**:e195–e203.
  18. **Von Dessauer B, Navarrete MS, Benadof D, Benavente C, Schmidt MG.** 2016. Potential effectiveness of copper surfaces in reducing health care-associated infection rates in a pediatric intensive and intermediate care unit: A nonrandomized controlled trial. *Am J Infect Control* **44**:e133–139.
  19. **Salgado CD, Sepkowitz KA, John JF, Cantey JR, Attaway HH, Freeman KD, Sharpe PA, Michels HT, Schmidt MG.** 2013. Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit. *Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am* **34**:479–486.
  20. Patient Protection and Affordable Care Act. Public Law 111-148. 111 ed. 2010.
  21. **Levy SB, Marshall B.** 2004. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med* **10**:S122–S129.
  22. **Warnes SL, Highmore CJ, Keevil CW.** 2012. Horizontal Transfer of Antibiotic Resistance Genes on Abiotic Touch Surfaces: Implications for Public Health. *mBio* **3**:e00489–12–e00489–12.
  23. **Mehtar S, Wiid I, Todorov SD.** 2008. The antimicrobial activity of copper and copper alloys against nosocomial pathogens and *Mycobacterium tuberculosis* isolated from healthcare facilities in the Western Cape: an in-vitro study. *J Hosp Infect* **68**:45–51.
  24. **Souli M, Galani I, Plachouras D, Panagea T, Armaganidis A, Petrikkos G, Giamarellou H.** 2013. Antimicrobial activity of copper surfaces against carbapenemase-producing contemporary Gram-negative clinical isolates. *J Antimicrob Chemother* **68**:852–857.
  25. **Eser OK, Ergin A, Hascelik G.** 2015. Antimicrobial Activity of Copper Alloys Against Invasive Multidrug-Resistant Nosocomial Pathogens. *Curr Microbiol* **71**:291–295.
  26. **Espirito Santo C, Morais PV, Grass G.** 2010. Isolation and characterization of bacteria resistant to metallic copper surfaces. *Appl Environ Microbiol* **76**:1341–1348.


27. **Espírito Santo C, Lam EW, Elowsky CG, Quaranta D, Domaille DW, Chang CJ, Grass G.** 2011. Bacterial killing by dry metallic copper surfaces. *Appl Environ Microbiol* **77**:794–802.
28. **Bleichert P, Espírito Santo C, Hanczaruk M, Meyer H, Grass G.** 2014. Inactivation of bacterial and viral biothreat agents on metallic copper surfaces. *Biometals Int J Role Met Ions Biol Biochem Med* **27**:1179–1189.
29. **San K, Long J, Michels CA, Gadura N.** 2015. Antimicrobial copper alloy surfaces are effective against vegetative but not sporulated cells of gram-positive *Bacillus subtilis*. *MicrobiologyOpen* **4**:753–763.
30. **Cui Z, Ibrahim M, Yang C, Fang Y, Annam H, Li B, Wang Y, Xie G-L, Sun G.** 2014. Susceptibility of Opportunistic *Burkholderia glumae* to Copper Surfaces Following Wet or Dry Surface Contact. *Mol Basel Switz* **19**:9975–9985.
31. **Ibrahim M, Wang F, Lou M, Xie G, Li B, Bo Z, Zhang G, Liu H, Wareth A.** 2011. Copper as an antibacterial agent for human pathogenic multidrug resistant *Burkholderia cepacia* complex bacteria. *J Biosci Bioeng* **112**:570–576.
32. **Faúndez G, Troncoso M, Navarrete P, Figueroa G.** 2004. Antimicrobial activity of copper surfaces against suspensions of *Salmonella enterica* and *Campylobacter jejuni*. *BMC Microbiol* **4**:19.
33. **Weaver L, Michels HT, Keevil CW.** 2008. Survival of *Clostridium difficile* on copper and steel: futuristic options for hospital hygiene. *J Hosp Infect* **68**:145–151.
34. **Wheeldon LJ, Worthington T, Lambert PA, Hilton AC, Lowden CJ, Elliott TSJ.** 2008. Antimicrobial efficacy of copper surfaces against spores and vegetative cells of *Clostridium difficile*: the germination theory. *J Antimicrob Chemother* **62**:522–525.
35. **Anderson, D.G., Michels, H.T.** 2008. Antimicrobial regulatory efficacy testing of solid copper alloy surfaces in the USA, p. 185–190. *In* Collery, P, Maynard, I., Thephanides, T, Khassanova, L., Collery, T. (eds.), *Metal Ions in Biology and Medicine*. John Libbey Eurotext.
36. **Tian W-X, Yu S, Ibrahim M, Almonaofy AW, He L, Hui Q, Bo Z, Li B, Xie G-L.** 2012. Copper as an antimicrobial agent against opportunistic pathogenic and multidrug resistant *Enterobacter* bacteria. *J Microbiol Seoul Korea* **50**:586–593.
37. **Gould SWJ, Fielder MD, Kelly AF, Morgan M, Kenny J, Naughton DP.** 2009. The antimicrobial properties of copper surfaces against a range of important nosocomial pathogens. *Ann Microbiol* **59**:151–156.
38. **Warnes SL, Green SM, Michels HT, Keevil CW.** 2010. Biocidal efficacy of copper alloys against pathogenic enterococci involves degradation of genomic and plasmid DNAs. *Appl Environ Microbiol* **76**:5390–5401.
39. **Warnes SL, Keevil CW.** 2013. Inactivation of norovirus on dry copper alloy surfaces. *PLoS One* **8**:e75017.
40. **Elguindi J, Wagner J, Rensing C.** 2009. Genes involved in copper resistance influence survival of

- Pseudomonas aeruginosa* on copper surfaces. *J Appl Microbiol* **106**:1448–1455.
41. **Molteni C, Abicht HK, Solioz M.** 2010. Killing of bacteria by copper surfaces involves dissolved copper. *Appl Environ Microbiol* **76**:4099–4101.
  42. **Wilks SA, Michels H, Keevil CW.** 2005. The survival of *Escherichia coli* O157 on a range of metal surfaces. *Int J Food Microbiol* **105**:445–454.
  43. **Hong R, Kang TY, Michels CA, Gadura N.** 2012. Membrane lipid peroxidation in copper alloy-mediated contact killing of *Escherichia coli*. *Appl Environ Microbiol* **78**:1776–1784.
  44. **Espírito Santo C, Taudte N, Nies DH, Grass G.** 2008. Contribution of copper ion resistance to survival of *Escherichia coli* on metallic copper surfaces. *Appl Environ Microbiol* **74**:977–986.
  45. **Weaver L, Michels HT, Keevil CW.** 2010. Potential for preventing spread of fungi in air-conditioning systems constructed using copper instead of aluminium. *Lett Appl Microbiol* **50**:18–23.
  46. **Guo Z, Han J, Yang X-Y, Cao K, He K, Du G, Zeng G, Zhang L, Yu G, Sun Z, He Q-Y, Sun X.** 2015. Proteomic analysis of the copper resistance of *Streptococcus pneumoniae*. *Met Integr Biometal Sci* **7**:448–454.
  47. **Rogers J, Dowsett AB, Dennis PJ, Lee JV, Keevil CW.** 1994. Influence of Plumbing Materials on Biofilm Formation and Growth of *Legionella pneumophila* in Potable Water Systems. *Appl Environ Microbiol* **60**:1842–1851.
  48. **Gião MS, Wilks SA, Keevil CW.** 2015. Influence of copper surfaces on biofilm formation by *Legionella pneumophila* in potable water. *Biomaterials Int J Role Met Ions Biol Biochem Med* **28**:329–339.
  49. **Abushelaibi A.** 2005. Antimicrobial effects of copper and brass ions on the growth of *Listeria monocytogenes* at temperatures, pH and nutrients. Louisiana State University.
  50. **Wilks SA, Michels HT, Keevil CW.** 2006. Survival of *Listeria monocytogenes* Scott A on metal surfaces: implications for cross-contamination. *Int J Food Microbiol* **111**:93–98.
  51. **Zhu L, Elguindi J, Rensing C, Ravishankar S.** 2012. Antimicrobial activity of different copper alloy surfaces against copper resistant and sensitive *Salmonella enterica*. *Food Microbiol* **30**:303–310.
  52. **Noyce JO, Michels H, Keevil CW.** 2006. Potential use of copper surfaces to reduce survival of epidemic methicillin-resistant *Staphylococcus aureus* in the healthcare environment. *J Hosp Infect* **63**:289–297.
  53. **Michels HT, Noyce JO, Keevil CW.** 2009. Effects of temperature and humidity on the efficacy of methicillin-resistant *Staphylococcus aureus* challenged antimicrobial materials containing silver and copper. *Lett Appl Microbiol* **49**:191–195.
  54. **Espírito Santo C, Quaranta D, Grass G.** 2012. Antimicrobial metallic copper surfaces kill *Staphylococcus haemolyticus* via membrane damage. *MicrobiologyOpen* **1**:46–52.


55. **Warnes SL, Little ZR, Keevil CW.** 2015. Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials. *mBio* **6**:e01697–15–e01697–15.
56. **Noyce JO, Michels H, Keevil CW.** 2007. Inactivation of influenza A virus on copper versus stainless steel surfaces. *Appl Environ Microbiol* **73**:2748–2750.
57. **Warnes SL, Summersgill EN, Keevil CW.** 2015. Inactivation of murine norovirus on a range of copper alloy surfaces is accompanied by loss of capsid integrity. *Appl Environ Microbiol* **81**:1085–1091.
58. **Manuel CS, Moore MD, Jaykus LA.** 2015. Destruction of the Capsid and Genome of GII.4 Human Norovirus Occurs during Exposure to Metal Alloys Containing Copper. *Appl Environ Microbiol* **81**:4940–4946.
59. **Li J, Dennehy JJ.** 2011. Differential bacteriophage mortality on exposure to copper. *Appl Environ Microbiol* **77**:6878–6883.
60. **Quaranta D, Krans T, Espírito Santo C, Elowsky CG, Domaille DW, Chang CJ, Grass G.** 2011. Mechanisms of contact-mediated killing of yeast cells on dry metallic copper surfaces. *Appl Environ Microbiol* **77**:416–426.

**Table 1.** Microorganisms that are known to die on copper alloy surfaces (taken from (8))


<b>Microorganism</b>	<b>Reference</b>
<b>Bacterial species</b>	
<i>Acinetobacter</i> species (MDR, other strains)	(23), (24), (25), (26)
<i>Bacillus anthrax</i> , <i>B. cereus</i> , <i>B. subtilis</i> (vegetative cells, not spores)	(27), (28), (29)
<i>Brachybacterium conglomeratum</i>	(26)
<i>Brucella melitensis</i>	(28)
<i>Burkholderia</i> species	(28), (30), (31)
<i>Campylobacter jejuni</i>	(32)
<i>Clostridium difficile</i> (vegetative cells, not spores)	(33), (34)
<i>Deinococcus radiodurans</i>	(27)
<i>Enterobacter</i> species	(24), (35), (36)
<i>Enterococci</i> species (vancomycin – resistant, other strains)	(37), (38), (39), (40), (41)
<i>Escherichia coli</i> (various strains)	(27), (37), (42), (43), (44)
<i>Francisella tularensis</i>	(28)
<i>Klebsiella pneumonia</i>	(22), (23), (24)
<i>Legionella pneumophila</i>	(45), (46), (47), (48)
<i>Listeria monocytogenes</i>	(49), (50)
<i>Mycobacterium tuberculosis</i>	(23)
<i>Pantoea stewartii</i>	(26)
<i>Pseudomonas</i> species	(24), (25), (26), (35), (37), (40)
<i>Salmonella enterica</i>	(32), (38), (51)
<i>Staphylococcus aureus</i> (MRSA, other strains); other <i>Staphylococcus</i> species	(25), (26), (37), (52), (53), (54)
<i>Yersinia pestis</i>	(28)
<b>Viruses</b>	
Coronavirus 229E (human)	(55)
Influenza A	(56)
Norovirus (murine, human)	(39), (57), (58)
T2 bacteriophage	(59)
Vaccinia, Monkeypox	(28)
<b>Fungi</b>	
<i>Aspergillus</i> species	(45)
<i>Candida albicans</i>	(23), (45), (60)
<i>Fusarium</i> species	(45)
<i>Penicillium chrysogenum</i>	(45)
<i>Saccharomyces cerevisiae</i>	(60)



**Figure 1:** Microbial burden found on the standard plastic rail (filled circles) and copper rail (open circles). The dashed line is the desired target microbial burden after terminal cleaning of 250 CFU/100 cm<sup>2</sup> (taken from (10)).



**Figure 2:** Microbial burden found on six objects in standard control rooms (dark gray bars) and copper rooms (light gray bars) in hospital intensive care units (ICUs) (taken from (16)).



**Figure 3.** Relationship between microbial burden measured in ICU rooms and the occurrences of hospital-acquired infects (HAIs) (taken from (19)).